{"id":19524,"date":"2021-12-15T02:05:00","date_gmt":"2021-12-15T02:05:00","guid":{"rendered":"https:\/\/eodishasamachar.com\/en\/2021\/12\/15\/arista-biotech-confirms-antigen-test-effectiveness-against-omicron-and-other-covid-variants\/"},"modified":"2021-12-15T02:05:00","modified_gmt":"2021-12-15T02:05:00","slug":"arista-biotech-confirms-antigen-test-effectiveness-against-omicron-and-other-covid-variants","status":"publish","type":"post","link":"https:\/\/eodishasamachar.com\/en\/2021\/12\/15\/arista-biotech-confirms-antigen-test-effectiveness-against-omicron-and-other-covid-variants\/","title":{"rendered":"ARISTA Biotech Confirms Antigen Test Effectiveness Against Omicron and other COVID variants"},"content":{"rendered":"<p> \n<\/p>\n<div lang=\"en\">\n<p>SINGAPORE<br \/>\n&#8211; <a href=\"https:\/\/www.media-outreach.com\/\">Media OutReach<\/a> &#8211; 15 December 2021 &#8211; <b><a href=\"https:\/\/aristabio.com\">ARISTA Biotech Pte Ltd<br \/>\n(&#8220;ARISTA&#8221;)<\/a>, manufacturer of COVID-19 antigen &amp; antibody diagnostics,<br \/>\nconfirms that its COVID-19 antigen rapid test, which tests for the presence of<br \/>\nSARS-CoV-2 virus in clinical specimens, is able to detect the recently identified<br \/>\nB.1.1.529 (Omicron) variant<\/b>.<\/p>\n<p>On<br \/>\n26th November 2021, the World Health Organization (WHO) announced and<br \/>\ndesignated variant B.1.1529 named Omicron, a newly identified variant first<br \/>\nidentified in Botswana and South Africa, as a Variant of Concern. Early<br \/>\nindication suggested this variant may have higher transmissibility and has<br \/>\nalready spread to over 30 countries in an accelerated manner.<\/p>\n<p>Sequence study of the Omicron variant confirmed that it<br \/>\nharbors more than 30 mutations across its genome with the majority of mutations<br \/>\nin the Spike protein. The Omicron variant possesses three replacement and one<br \/>\ndeletion mutations in the N-protein compared to the original viral strain<br \/>\n(Table 1).<\/p>\n<p align=\"center\"><img width=\"500\" data-src=\"https:\/\/images.media-outreach.com\/Thumb\/500x0\/207035\/Arista-table2.jpeg#image-207035\" class=\"lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\"\/><\/p>\n<p><noscript><img src=\"https:\/\/images.media-outreach.com\/Thumb\/500x0\/207035\/Arista-table2.jpeg#image-207035\" width=\"500\"\/><\/noscript><\/p>\n<p>The ARISTA TM COVID-19 Antigen Rapid Test is designed to<br \/>\nidentify the presence of SARS-CoV-2 virus in clinical specimens by detecting<br \/>\nthe nucleocapsid protein (N-protein) in the core of the virus. ARISTA has<br \/>\nconducted studies using recombinant variant N-proteins to validate and confirm<br \/>\nthe ARISTA COVID-19 Antigen Rapid Test is able to detect over 400+ variants,<br \/>\nincluding B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617, B.1.617.2<br \/>\n(Delta), AY.1\/AY.2\/AY.3 (Delta Plus), B.1.617.3, C.37 (Lambda) and B.1.1.529<br \/>\n(Omicron) with similar sensitivities (Table 2).<\/p>\n<p>Our preliminary laboratory results indicate that the<br \/>\nsensitivity of the ARISTA COVID-19 Antigen Test remains similar for all<br \/>\nvariants tested to date &#8211; including the Omicron variant. Further performance<br \/>\nvalidation results and clinical studies on the Omicron variant are underway and<br \/>\nwill be made available in due course.<\/p>\n<p><b>Letter of Statement<\/b><\/p>\n<p>ARISTA\u2122 COVID-19 Antigen Rapid Test is designed<br \/>\nto detect the presence of SARS-CoV-2 virus in a clinical specimen by identifying<br \/>\nthe nucleocapsid protein (N-protein) of SARS-CoV-2 viral antigen and is used as<br \/>\nan aid in rapid screening of COVID-19 infection. As the product manufacturer, ARISTA<br \/>\nBiotech Pte Ltd (&#8220;ARISTA&#8221;) is responsible for the performance of the product<br \/>\nand ensures it can be effective against all key emerging variants.<\/p>\n<p>On 26<sup>th<\/sup> November 2021, the World<br \/>\nHealth Organization (WHO) announced and designated variant B.1.1529 named Omicron, a newly identified<br \/>\nvariant from Botswana and South Africa, as a Variant of Concern. Early<br \/>\nindications suggest this variant to have higher transmissibility and has already<br \/>\nspread through multiple countries in an accelerated manner.<\/p>\n<p>Sequence study of the Omicron variant<br \/>\nconfirms that it harbors more than 30 mutations across its genome with the majority<br \/>\nof the mutations in the Spike protein. The Omicron variant possess three<br \/>\nreplacement and one deletion mutations in the N-protein compared to the<br \/>\noriginal viral strain.<\/p>\n<p>ARISTA continues to monitor and validate the<br \/>\nproduct&#8217;s performance against all major emerging variants, and we hereby<br \/>\nconfirm that the ARISTA<sup>TM<\/sup> COVID-19 Antigen Rapid Test product<br \/>\ncontinue to detect the Omicron variant with no loss in sensitivity.<\/p>\n<p>ARISTA has conducted studies using recombinant<br \/>\nvariant N-proteins to validate and confirm similar detection sensitivity on B.1.1.7<br \/>\n(Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617, B.1.617.2 (Delta),<br \/>\nAY.1\/AY.2\/AY.3 (Delta Plus), B.1.617.3, C.37 (Lambda) and B.1.529 (Omicron).<\/p>\n<p>ARISTA will conduct further molecular<br \/>\nvalidation and field clinical studies to demonstrate the clinical performance<br \/>\nof the ARISTA product towards the Delta and Omicron variants. We will continue to<br \/>\nmonitor the emerging variants and evaluate the performance of ARISTA\u2122 COVID-19<br \/>\nAntigen Rapid Test against new important variants as they emerge.\u00a0 Further information will be shared when<br \/>\navailable.<\/p>\n<p>Dr. Eric Tang<\/p>\n<p>Chief<br \/>\nScientific Officer<\/p>\n<p>ARISTA Biotech<br \/>\nPte. Ltd.<\/p>\n<p>1<sup>st<\/sup> December<br \/>\n2021<\/p>\n<\/p><\/div>\n\n<br \/><a href=\"https:\/\/www.media-outreach.com\/news\/2021-12-15\/111240\/arista-biotech-confirms-antigen-test-effectiveness-against-omicron-and-other-covid-variants\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SINGAPORE &#8211; Media OutReach &#8211; 15 December 2021 &#8211; ARISTA Biotech Pte Ltd (&#8220;ARISTA&#8221;), manufacturer of COVID-19 antigen &amp; antibody diagnostics, confirms that its COVID-19 antigen rapid test, which tests for the presence of SARS-CoV-2 virus in clinical specimens, is able to detect the recently identified B.1.1.529 (Omicron) variant. On 26th November 2021, the World &hellip;<\/p>\n","protected":false},"author":1,"featured_media":19525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/19524"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=19524"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/19524\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media\/19525"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=19524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=19524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=19524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}